EMA clears Greenwich Lifesciences’ commercially manufactured GP2 for use in FLAMINGO-01 trial in Europe

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

GLSI

0.00
  • EMA review cleared use of Greenwich LifeSciences’ commercially manufactured GP2 lot in the Phase III FLAMINGO-01 breast cancer recurrence trial in Europe.
  • Move aligns European sites with the US, where FDA review previously allowed the same GP2 vial lot for FLAMINGO-01 use in early 2026.
  • Company now pursuing separate regulatory clearances to use the lot in the UK and Canada.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607090600PRIMZONEFULLFEED9759574) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.